Introduction Coronavirus disease 2019 (COVID-19) is a multisystem process with a growing evidence of its endotheliopathy effects, with subsequent hypercoagulability states. Case Report WWe present an emergency department case of a COVID-19-provoked deep venous thrombosis and pulmonary embolism without a history of venous thromboembolism (VTE), with extension of the VTE despite adherence to apixaban. Conclusion This case demonstrates the importance of further research and protocols for optimal dosage and treatment to prevent worsening VTE in COVID-19 patients.
All Keywords
【저자키워드】 COVID-19, endotheliopathy, Venous Thromboembolism, Case report, apixaban, 【초록키워드】 Treatment, Coronavirus disease 2019, protocol, Research, Deep venous thrombosis, hypercoagulability, COVID-19 patients, Evidence, VTE, dosage, worsening, report, extension, Effects, Prevent, subsequent, 【제목키워드】 report, break,
【저자키워드】 COVID-19, endotheliopathy, Venous Thromboembolism, Case report, apixaban, 【초록키워드】 Treatment, Coronavirus disease 2019, protocol, Research, Deep venous thrombosis, hypercoagulability, COVID-19 patients, Evidence, VTE, dosage, worsening, report, extension, Effects, Prevent, subsequent, 【제목키워드】 report, break,